Meanwhile, LARS promoted tumor growth and raised the expression of LA (the product of glycolysis) and that of HK2, GLUT1, and HIF-1α, the key enzymes in glycolysis, which were reversed upon 2-DG treatment. The gene discussed is HIF1A; the disease is neoplasm.